IN8bio, Inc., a clinical-stage biopharmaceutical company, announced today it has secured $40.2 million in new funding from investors. This significant capital infusion is earmarked to support the advancement of its innovative therapeutic programs focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer.
The company's work centers on gamma-delta T cells, which are naturally occurring immune cells embodying properties of both the innate and adaptive immune systems. This unique characteristic allows them to intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells through its proprietary DeltEx platform, leveraging deep expertise in gamma-delta T cell biology, genetic engineering, and cell-type specific manufacturing capabilities. The platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies designed to effectively identify and eradicate tumor cells. IN8bio is currently recognized as the most clinically advanced gamma-delta T cell company and holds the distinction of being the first to bring genetically modified gamma-delta T cells into the clinic.
The newly raised capital will be strategically deployed to accelerate the development of IN8bio's pipeline, fund ongoing clinical trials, and expand its research and development efforts. This funding round underscores investor confidence in the potential of IN8bio's DeltEx platform to deliver transformative cancer treatments. The company plans to utilize these funds to further its growth initiatives and continue its mission to develop novel cell therapies that could significantly impact patient outcomes in the fight against cancer.
.png&w=3840&q=75)
